2023
Loss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group
Puthenpura V, Ji L, Xu X, Roth M, Freyer D, Frazier A, Marks A, Pashankar F. Loss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group. Cancer 2023, 129: 1547-1556. PMID: 36813754, PMCID: PMC10357561, DOI: 10.1002/cncr.34701.Peer-Reviewed Original ResearchConceptsClinical trial participantsNon-Hispanic blacksTrial participantsHazard ratioOncology GroupClinical trialsMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelChildren's Oncology Group trialsProportional hazards regression modelsYoung adultsAdjusted hazard ratioChildren's Oncology GroupLong-term complicationsLong-term outcomesLog-rank testHazards regression modelsPediatric clinical trialsCancer clinical trial participantsLow socioeconomic status areasLong-term survivalEthnic minority patientsQuality of lifeLow socioeconomic statusNon-Hispanic whites
2022
Sense of mastery and attitude towards illness: Examining longitudinal benefits of a medical specialty camp for youth with sickle cell disease
Gillard A, Gagnon R, Pashankar F, Balsamo L, Grafft N, Miranda J, Boruchov D, Neri C, Sprinz P, Longyear C. Sense of mastery and attitude towards illness: Examining longitudinal benefits of a medical specialty camp for youth with sickle cell disease. Clinical Child Psychology And Psychiatry 2022, 28: 1012-1023. PMID: 36503316, DOI: 10.1177/13591045221145425.Peer-Reviewed Original ResearchUtility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group
Dicken B, Billmire D, Rich B, Hazard F, Nuño M, Krailo M, Fallahazad N, Pashankar F, Shaikh F, Frazier A. Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group. Gynecologic Oncology 2022, 166: 476-480. PMID: 35750503, PMCID: PMC9514449, DOI: 10.1016/j.ygyno.2022.06.013.Peer-Reviewed Original ResearchConceptsIntra-operative frozen sectionOvarian germ cell tumorsGerm cell tumorsMalignant ovarian germ cell tumorsIntra-operative frozen section diagnosisFrozen section diagnosisCentral pathology reviewCell tumorsSurgical stagingAdolescent patientsFinal diagnosisFinal paraffin section diagnosisSection diagnosisFrozen sectionsParaffin section diagnosisOncology GroupPathology reviewCentral reviewOvarian germ cell malignanciesNonseminomatous germ cell tumorsGerm cell tumor componentsConfirmation of malignancyGerm cell malignanciesRecords of patientsChildren's Oncology Group
2021
Prevalence and risk factors of cognitive impairment in children with sickle cell disease in Egypt
Youssry I, ElGhamrawy M, Seif H, Balsamo L, Pashankar F, Mahrous M, Salama N. Prevalence and risk factors of cognitive impairment in children with sickle cell disease in Egypt. International Journal Of Hematology 2021, 115: 399-405. PMID: 34792734, DOI: 10.1007/s12185-021-03260-1.Peer-Reviewed Original ResearchConceptsSickle cell diseaseHigh lactate dehydrogenaseCell diseaseCognitive impairmentRisk factorsLactate dehydrogenaseCairo University Children's HospitalOlder ageSickle cell disease patientsUniversity Children's HospitalPossible risk factorsMagnetic resonance angiographyMagnetic resonance imagingHydroxyurea therapyTranscranial DopplerChildren's HospitalDisease patientsUnivariate analysisEarly initiationPatientsResonance angiographyImpaired cognitionResonance imagingIntelligence quotient (IQ) testDiseaseTreatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol
Rodriguez-Galindo C, Krailo MD, Pinto EM, Pashankar F, Weldon CB, Huang L, Caran EM, Hicks J, McCarville MB, Malkin D, Wasserman JD, de Oliveira Filho AG, LaQuaglia MP, Ward DA, Zambetti G, Mastellaro MJ, Pappo AS, Ribeiro RC. Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol. Journal Of Clinical Oncology 2021, 39: 2463-2473. PMID: 33822640, PMCID: PMC8462560, DOI: 10.1200/jco.20.02871.Peer-Reviewed Original ResearchConceptsRetroperitoneal lymph node dissectionLymph node dissectionOutcomes of patientsAdrenocortical carcinomaNode dissectionStage IOncology GroupStage IV adrenocortical carcinomaStage-III adrenocortical carcinomaPediatric-specific studiesStage II diseaseEvent-free survivalStage II patientsThird of patientsOverall survival estimatesChildren's Oncology GroupHigh-risk groupCombination of mitotaneAggressive pediatric malignancyPediatric adrenocortical carcinomaAdvanced diseaseII patientsMultivariable analysisPoor outcomeExcellent outcomesRacial/ethnic, socioeconomic, and geographic survival disparities in adolescents and young adults with primary central nervous system tumors
Puthenpura V, Canavan ME, Poynter JN, Roth M, Pashankar FD, Jones BA, Marks AM. Racial/ethnic, socioeconomic, and geographic survival disparities in adolescents and young adults with primary central nervous system tumors. Pediatric Blood & Cancer 2021, 68: e28970. PMID: 33704901, PMCID: PMC8221084, DOI: 10.1002/pbc.28970.Peer-Reviewed Original ResearchConceptsHazard of deathCentral nervous system tumorsNervous system tumorsRace/ethnicitySocioeconomic statusSystem tumorsMultivariate Cox proportional hazards modelNon-Hispanic black patientsNon-Hispanic white patientsPrimary central nervous system tumorsCox proportional hazards modelEnd Results (SEER) databaseRetrospective cohort studyPrimary CNS tumorsYoung adult patientsNeuro-oncology patientsProportional hazards modelLowest SES tertileLow socioeconomic statusNHB patientsAYA patientsHazard ratioNHW patientsAdult patientsCohort study
2020
Emotion regulation, pain interference and affective symptoms in children and adolescents with sickle cell disease
Miller M, Balsamo L, Pashankar F, Bailey CS. Emotion regulation, pain interference and affective symptoms in children and adolescents with sickle cell disease. Journal Of Affective Disorders 2020, 282: 829-835. PMID: 33601724, DOI: 10.1016/j.jad.2020.12.068.Peer-Reviewed Original ResearchConceptsEmotion regulation strategiesEmotion Regulation QuestionnaireCognitive Emotion Regulation QuestionnaireMaladaptive emotion regulation strategiesSelf-report measuresSymptoms of depressionRegulation strategiesEmotion regulationYouth self-report measuresPain interferenceParticipants ages 8Symptoms of anxietyExperience of painPsychological functioningOutcomes Measurement Information SystemAge 8Measurement Information SystemAnxietyAffective symptomsYouthDepressionAffective disordersPediatric sickle cell clinicParticipantsMultiple regression modelImaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant Histology
Billmire D, Dicken B, Rescorla F, Ross J, Piao J, Huang L, Krailo M, Pashankar F, Frazier L, Group C. Imaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant Histology. Journal Of Pediatric And Adolescent Gynecology 2020, 34: 383-386. PMID: 33316416, PMCID: PMC8096645, DOI: 10.1016/j.jpag.2020.11.014.Peer-Reviewed Original ResearchConceptsMalignant ovarian germ cell tumorsMalignant germ cell tumorsGerm cell tumorsOvarian germ cell tumorsCell tumorsOncology GroupMalignant histologyImaging appearancesExtracranial malignant germ cell tumorsNonseminomatous malignant germ cell tumorsOvarian malignant germ cell tumorsSolid appearanceComplete surgical stagingElement of teratomaPediatric ovarian neoplasmsPreoperative serum markersChildren's Oncology GroupPrimary ovarian tumorsYolk sac tumorYears of ageAssociated teratomaTeratoma elementsSurgical stagingMixed histologyMulticenter trialPatterns of medication use at end of life by pediatric inpatients with cancer
Prozora S, Shabanova V, Ananth P, Pashankar F, Kupfer GM, Massaro SA, Davidoff AJ. Patterns of medication use at end of life by pediatric inpatients with cancer. Pediatric Blood & Cancer 2020, 68: e28837. PMID: 33306281, DOI: 10.1002/pbc.28837.Peer-Reviewed Original ResearchConceptsMedication usePediatric inpatientsVizient Clinical Database/Resource ManagerHematopoietic stem cell transplantLife-sustaining medicationsMedication utilization patternsSymptom management medicationsUse of opioidsStem cell transplantIntensive care unitLength of stayAcademic medical centerResource use dataLast weekWarrants further studyEvidence-based approachVasopressor useEnd of lifeCare unitCell transplantMedication categoriesResuscitate statusRetrospective studyMalignancy typeOdds ratioOutcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium
Shaikh F, Stark D, Fonseca A, Dang H, Xia C, Krailo M, Pashankar F, Rodriguez‐Galindo C, Olson TA, Nicholson JC, Murray MJ, Amatruda JF, Billmire D, Stoneham S, Frazier AL. Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium. Cancer 2020, 127: 193-202. PMID: 33079404, DOI: 10.1002/cncr.33273.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolHumansInfantInfant, NewbornLymphatic MetastasisMaleMediastinal NeoplasmsNeoplasms, Germ Cell and EmbryonalProgression-Free SurvivalRetroperitoneal NeoplasmsRetrospective StudiesTesticular NeoplasmsYoung AdultConceptsMetastatic germ cell tumorsEvent-free survivalGerm cell tumorsCell tumorsRisk groupsYoung adultsAge groupsMale patientsAdolescent patientsAdolescent malesCox proportional hazards analysisMalignant germ cell tumorsIndividual patient databasePlatinum-based chemotherapyProportional hazards analysisYoung adult patientsClinical trial organizationsAdolescent age groupPediatric cooperative groupsTreatment of adolescentsDifferent age groupsAdult patientsClinical characteristicsEFS rateInclusion criteria
2019
Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study.
Rodriguez-Galindo C, Krailo MD, Krasin MJ, Huang L, McCarville MB, Hicks J, Pashankar F, Pappo AS. Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study. Journal Of Clinical Oncology 2019, 37: 3369-3376. PMID: 31553639, PMCID: PMC6920031, DOI: 10.1200/jco.19.01276.Peer-Reviewed Original ResearchConceptsEvent-free survivalChildhood nasopharyngeal carcinomaInduction chemotherapyConcurrent chemoradiotherapyStage IIBNasopharyngeal carcinomaCycles of ICCancer stage IIBPediatric-specific studiesCycles of cisplatinOverall survival estimatesAmerican Joint CommitteeDoses of cisplatinCumulative incidence estimatesRadiation dose reductionAdult regimensStable diseaseAdvanced diseasePartial responseMedian ageExcellent outcomesIncidence estimatesDose reductionPatientsJoint Committeeα‐Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium
O’Neill A, Xia C, Krailo MD, Shaikh F, Pashankar FD, Billmire DF, Olson TA, Amatruda JF, Villaluna D, Huang L, Malogolowkin M, Rodriguez‐Galindo C, Frazier AL. α‐Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium. Cancer 2019, 125: 3649-3656. PMID: 31355926, DOI: 10.1002/cncr.32363.Peer-Reviewed Original ResearchConceptsGerm cell tumorsChildren's Oncology GroupCell tumorsAFP declineCumulative incidenceOncology GroupOverall survivalPediatric patientsThree-year overall survivalFuture clinical trial designTumor marker declineStart of chemotherapyPredictors of outcomeRecognition of patientsClinical trial designYears of ageAdult patientsPoor prognosisSerum AFPMarker declineStratified analysisHigh riskTrial designPatientsEarly intensificationGrowing Teratoma Syndrome After Chemotherapy For Ovarian Immature Teratoma
Imran H, Siddiqui AH, Wilson F, Pashankar F. Growing Teratoma Syndrome After Chemotherapy For Ovarian Immature Teratoma. Journal Of Pediatric Hematology/Oncology 2019, 42: e630-e633. PMID: 31205224, DOI: 10.1097/mph.0000000000001525.Peer-Reviewed Original ResearchConceptsOvarian immature teratomaRecurrent immature teratomaImmature teratomaTeratoma syndromePediatric patientsMainstay of treatmentPostoperative chemotherapyGynecologic oncologistsPediatric oncologistsAdult providersChemotherapyPatientsOncologistsSyndromeTeratomaAdultsTreatmentSurgeryRecurrenceManagementMainstay
2018
Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group
Fonseca A, Xia C, Lorenzo AJ, Krailo M, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Billmire DF, Rodriguez-Galindo C, Frazier AL, Shaikh F. Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group. Journal Of Clinical Oncology 2018, 37: 396-402. PMID: 30576269, PMCID: PMC6553816, DOI: 10.1200/jco.18.00790.Peer-Reviewed Original ResearchConceptsMalignant germ cell tumorsTumor marker elevationNongerminomatous malignant germ cell tumorsAbnormal tumor markersGerm cell tumorsMarker elevationTumor markersRelapse surveillanceOncology GroupInitial diagnosisCell tumorsChildren's Oncology GroupDetection of relapseSingle-arm trialNormal tumor markersCase report formsAbnormal imagingCentral reviewMarker levelsPathology reportsRelapsePatientsPhase IIIReport formsComplete dataProtocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours
Lawrence NJ, Chan H, Toner G, Stockler MR, Martin A, Yip S, Wong N, Yeung A, Mazhar D, Pashankar F, Frazier L, McDermott R, Walker R, Tan H, Davis ID, Grimison P, on behalf of ANZUP. Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours. BMC Cancer 2018, 18: 854. PMID: 30157803, PMCID: PMC6114870, DOI: 10.1186/s12885-018-4745-3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCisplatinClinical ProtocolsClinical Trials, Phase III as TopicEtoposideFemaleHumansInfantInfant, NewbornMaleMulticenter Studies as TopicNeoplasms, Germ Cell and EmbryonalRandomized Controlled Trials as TopicResearch DesignYoung AdultConceptsPoor-risk metastatic germ cell tumoursMetastatic germ cell tumorsGerm cell tumorsStandard BEP chemotherapyFirst-line chemotherapyCell tumorsLine chemotherapyBEP chemotherapyCure rateClinical trialsPoor-risk germ cell tumorsMulticentre phase 2 trialRandomised phase 3 trialStandard first-line treatmentPhase 3 clinical trialsComplete response rateFirst-line treatmentPhase 2 trialPhase 3 trialProgression-free survivalHealth-related qualityPediatric age groupFemale participantsInternational multicentreStandard BEPIs carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?
Shah R, Xia C, Krailo M, Amatruda JF, Arul SG, Billmire DF, Brady WE, Covens A, Gershenson DM, Hale JP, Hurteau J, Murray MJ, Nicholson JC, Olson TA, Pashankar F, Rodriguez-Galindo C, Shaikh F, Stark D, Frazier AL, Stoneham S. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults? Gynecologic Oncology 2018, 150: 253-260. PMID: 29884437, DOI: 10.1016/j.ygyno.2018.05.025.Peer-Reviewed Original ResearchConceptsCisplatin-based chemotherapyClinical trial organizationsGerm cell tumorsFive-year event-free survivalMalignant ovarian germ cell tumorsOvarian germ cell tumorsAge groupsCarboplatin-based chemotherapyTreatment-related toxicityEvent-free survivalEligible patientsExcellent OSMetastatic diseaseOverall survivalClinical outcomesFrontline treatmentSurvival outcomesMean agePeak incidenceCell tumorsDysgerminomaChemotherapyPatientsTrials OrganizationCarboplatinComparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium
Frazier AL, Stoneham S, Rodriguez-Galindo C, Dang H, Xia C, Olson TA, Murray MJ, Amatruda JF, Shaikh F, Pashankar F, Billmire D, Krailo M, Stark D, Brougham MFH, Nicholson JC, Hale JP. Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium. European Journal Of Cancer 2018, 98: 30-37. PMID: 29859339, DOI: 10.1016/j.ejca.2018.03.004.Peer-Reviewed Original ResearchConceptsChildren's Oncology GroupEvent-free survivalOncology GroupClinical trialsGerm cell tumor patientsCarboplatin-based regimensCisplatin-based regimensParametric cure modelsLeukemia groupTumor patientsStandard riskChildren's CancerRegimensCancerRiskTrialsGroupCure modelPatientsCarboplatinInternational ConsortiumCisplatinTreatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 study
Pashankar F, Frazier AL, Krailo M, Xia C, Pappo AS, Malogolowkin M, Olson TA, Rodriguez‐Galindo C. Treatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 study. Pediatric Blood & Cancer 2018, 65: e27111. PMID: 29697191, PMCID: PMC6019185, DOI: 10.1002/pbc.27111.Peer-Reviewed Original ResearchConceptsMalignant germ cell tumorsPediatric malignant germ cell tumorsGerm cell tumorsOncology GroupCell tumorsMarker declineRefractory germ cell tumorsHigh-dose chemotherapyPhase II trialChildren's Oncology GroupGroup of patientsLong-term toxicityRECIST responseSalvage therapyStable diseaseTIP regimenII trialRECIST criteriaElevated markersPartial responseProgressive diseaseStandard therapyAdditional administrationTumor markersPatientsOvarian Yolk Sac Tumors; Does Age Matter?
Conter C, Xia C, Gershenson D, Hurteau J, Covens A, Pashankar F, Krailo M, Billmire D, Patte C, Fresneau B, Shaikh F, Stoneham S, Nicholson J, Murray M, Frazier AL. Ovarian Yolk Sac Tumors; Does Age Matter? International Journal Of Gynecological Cancer 2018, 28: 77-84. PMID: 29194189, DOI: 10.1097/igc.0000000000001149.Peer-Reviewed Original ResearchConceptsOvarian yolk sac tumorEvent-free survivalYolk sac tumorOverall survivalSac tumorClinical trialsOvarian germ cell tumorsPreoperative alpha-fetoprotein levelAge cut pointStage IV diseaseAdverse prognostic factorPlatinum-based chemotherapyAlpha-fetoprotein levelsCut pointsGerm cell tumorsPediatric clinical trialsRisk of eventsOptimal cut pointJoint pediatricChemosensitive tumorsChemotherapeutic regimenPrognostic impactPrognostic factorsAdult trialsGynecologic oncologists
2017
Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study
Dicken BJ, Billmire DF, Krailo M, Xia C, Shaikh F, Cullen JW, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Rescorla FJ, Egler RA, Ross JH, Rodriguez‐Galindo C, Frazier AL. Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study. Pediatric Blood & Cancer 2017, 65 PMID: 29286555, PMCID: PMC6219870, DOI: 10.1002/pbc.26913.Peer-Reviewed Original ResearchConceptsOvarian germ cell tumorsMalignant ovarian germ cell tumorsGerm cell tumorsEvent-free survivalNon-GD patientsOverall survivalGonadal dysgenesisMalignant germ cell tumorsAggressive chemotherapy regimenHigh-risk groupNondysgerminomatous tumorsChemotherapy regimenPure dysgerminomaPediatric patientsSac tumorBilateral gonadectomyCell tumorsWorse outcomesEmbryonal carcinomaPatientsStreak ovariesDysgenetic gonadsTumorsY chromosome materialGonadoblastoma